

Evidence dossier - Deerfield Management

GetCoattail manager profile: <https://getcoattail.com/manager/deerfield-management> | CIK 0001009258 | Rank #53 of 149 tracked managers by reported 13F value.

Background: Founded: 1994 | HQ: New York City, NY | Style: Healthcare-focused investing across public equity, venture capital, private equity and private credit | Key person: James Flynn

Background source: https://en.wikipedia.org/wiki/Deerfield_Management

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-14 Reported total value: \$9.6B Positions: 82 Top-10 concentration: 53.2% of reported value.

Ticker	Company	Weight	Reported value
	Nuvalent Inc	22.22%	\$2.1B
BKD	Brookdale Sr Living Inc	6.11%	\$586M
RVMD	Revolution Medicines Inc	4.67%	\$448M
PRAX	Praxis Precision Medicines I	3.36%	\$323M
VTRS	Viatis Inc	3.35%	\$321M
CNC	Centene Corp Del	3.28%	\$315M
RVMD	Revolution Medicines Inc	2.63%	\$252M
UTHR	United Therapeutics Corp Del	2.58%	\$248M
ARWR	Arrowhead Pharmaceuticals In	2.51%	\$241M
LEGN	Legend Biotech Corp	2.45%	\$235M

2. Hypothetical 13F-clone results

WITHHELD for this manager. Price coverage of the disclosed portfolio is too low for a representative clone (latest-filing value coverage and the average unpriced segment weight are stated in section 4): a clone computed from the priced minority would misrepresent the disclosed portfolio. The filing snapshot above and the filing history below are complete as reported.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q3	0001140361-16-086449	2016-11-14	82
2016Q4	0001140361-17-007402	2017-02-14	89
2017Q1	0001140361-17-020638	2017-05-15	89
2017Q2	0001140361-17-031950	2017-08-14	72
2017Q3	0001140361-17-042010	2017-11-13	78
2017Q4	0001140361-18-008191	2018-02-14	85

2018Q1	0001140361-18-023958	2018-05-15	99
2018Q2	0001567619-18-001075	2018-08-14	99
2018Q3	0001567619-18-006280	2018-11-14	92
2018Q4	0001567619-19-004367	2019-02-14	88
2019Q1	0001567619-19-011266	2019-05-15	82
2019Q2	0001567619-19-016972	2019-08-14	86
2019Q3	0000950159-19-000232	2019-11-14	86
2019Q4	0000950159-20-000051	2020-02-14	70
2020Q1	0000950159-20-000137	2020-05-15	80
2020Q2	0000950159-20-000206	2020-08-14	86
2020Q3	0000950159-20-000284	2020-12-30	92
2020Q4	0000950159-21-000090	2021-02-16	120
2021Q1	0000950159-21-000154	2021-05-17	115
2021Q2	0000950159-21-000256	2021-08-16	121
2021Q3	0000950159-21-000326	2021-11-15	110
2021Q4	0000950159-22-000077	2022-02-14	104
2022Q1	0000950159-22-000122	2022-05-16	99
2022Q2	0000950159-22-000199	2022-08-15	99
2022Q3	0000950159-22-000241	2022-11-14	104
2022Q4	0000950159-23-000074	2023-02-14	81
2023Q1	0000950159-23-000173	2023-05-15	86
2023Q2	0000950159-23-000249	2023-08-14	85
2023Q3	0000950159-23-000305	2023-11-14	75
2023Q4	0000950159-24-000096	2024-02-14	215
2024Q1	0000950159-24-000176	2024-05-15	361
2024Q2	0000950159-24-000249	2024-08-14	426
2024Q3	0001213900-24-098387	2024-11-14	437
2024Q4	0001213900-25-014236	2025-02-14	99
2025Q1	0001213900-25-044138	2025-05-15	115
2025Q2	0001213900-25-076586	2025-08-14	116
2025Q3	0001213900-25-110851	2025-11-14	144
2025Q4	0001213900-26-017265	2026-02-17	141
2026Q1	0001213900-26-057678	2026-05-15	73
2026Q2	0001213900-26-089991	2026-08-14	72

4. Coverage and adjustments

Price coverage at the latest filing: 64.2% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.